In this issue of Neuron, Tochitsky et al. (2016) have identified the mechanism by which small-molecule photoswitches enter and specifically activate retinal OFF-ganglion cells in degenerated retinas. This drug development is a tremendous step toward the treatment of blindness, regardless of the underlying mutation.
The retina is the neural tissue at the back of the eye that captures the visual panorama. There are many hereditary diseases, such as retinitis pigmentosa (RP) , that lead to blindness. RP is a genetically complex disease manifested by any one of more than 200 mutations. These mutations result in a common pathology, the progressive degeneration of the retina. Primarily rod photoreceptors, which are important for low-light vision, are affected by these mutations and degenerate. As the disease progresses, cone photoreceptors that mediate high acuity, daylight, and color vision become light insensitive and eventually also degenerate. At this stage of blindness, retinal remodeling occurs that progressively alters anatomical, biochemical, and functional features of the retina (Jones et al., 2016) . There is no general therapeutic intervention available at present to restore visual function in RP.
Due to the high genetic complexity and the progressive nature of retinal degeneration, therapeutic interventions are challenging. The ideal option would be to substitute the mutated allele(s) by genereplacement or gene-editing strategies prior to disease onset. Gene replacement involves the delivery of a wild-type copy to the affected cells to restore visual function and to prevent any further degeneration (Sahel and Roska, 2013) . However, if a mutation is dominant, it is also necessary to silence the mutated gene product. Gene editing depends on the intrinsic DNA repair machinery, which limits gene correction by homologdirected repair in postmitotic neurons; gene disruption via non-homologous end-joining, on the other hand, can be very efficient in retinal cells (Hung et al., 2016) . A promising mutation-independent approach to restoring visual function is the application of optogenetic tools that confer light sensitivity to all targeted retinal cell types. In this way, and in the absence of intrinsic photoreceptors, targeted inner-retinal cell types become artificial photoreceptors (Klapper et al., 2016) . A more invasive approach is the transplantation of electrical implants at late stages of RP, which results in the recovery of some visual function in RP patients (Chuang et al., 2014) . Cellreplacement strategies aim to substitute lost photoreceptors or retinal pigment epithelium cells (Jayakody et al., 2015) . Another promising option is to stop, or significantly delay, the onset and progression of the degeneration by applying neuroprotective factors that outpace the devastating effects of the primary mutations (Sahel and Roska, 2013) . A combined functional and neuroprotective approach will likely be required to stop further retinal degeneration and restore visual perception.
In summary, there are many therapeutic interventions for RP currently under clinical evaluation or already being used to treat patients. However, these therapies depend on invasive surgeries, such as transplanting implants or injecting recombinant viral particles that carry a DNAencoded cargo to targeted cell types in the eye.
Ideally, it would be better to have a small-molecule drug that restores visual function and can be either administered systemically or injected locally into the eye. Promising molecules have been described in pioneering studies; these photoisomerizable molecules bind to ion channels or receptors, thereby serving as photoswitches that render the endogenous proteins light sensitive. The photoisomerization can exert forces on the channels and receptors, as well as adding or removing ligands. These effects lead to channel activation and subsequently to neuronal activation when a certain depolarization threshold is reached (Kramer et al., 2009 ). These optochemical molecules have been generated by synthetic chemistry and applied to blind retinas, where they have restored some visual function (Tochitsky and Kramer, 2015) , although the specificity of targeted cell types and the mechanism of cell entry were unknown. Targeting specific retinal cells for functional reactivation is of tremendous importance, since there are two major signal pathways in the retina: the OFF pathway, which is activated by decrements of light, and the ON pathway, which is activated by increments of light. In addition, there is significant signal processing by inhibitory neurons in the retina (Gollisch and Meister, 2010) . Any unspecific activation of both ON and OFF pathways may confuse the interpretation of incoming light information in higher brain areas. Tochitsky et al. (2016) , after undertaking extensive pharmaceutical and genetic manipulations, have now discovered the mechanism by which photoswitches specifically enter OFF-ganglion cells in diseased mouse retinas. The uptake of charged optochemical compounds occurs via P2X receptors. There are seven P2X receptor isoforms, of which six are expressed in the retina, including two variants that were found to be significantly upregulated in diseased retinas. Although ON-ganglion cells in degenerated retinas also express P2X receptors, these cells remain impermeable to photoswitches. This was also the case for both ON-and OFF-ganglion cells in healthy retinas, suggesting that there must be a disease-specific activation (a functional remodeling) of P2X receptors in OFF-ganglion cells. Hence, activated P2X receptors act like gatekeepers, in a safety feature restricting photoswitch uptake to OFF-ganglion cells in RP retinas.
Next, the photoswitches have to bind to intrinsic ion channels to mediate lightinducible neuronal activity. Photoswitches have different channel preferences. For example, DENAQ prefers hyperpolarization-activated cyclic nucleotide-gated (HCN) channels (Figure 1 ). Since direct administration of these compounds into ON-ganglion cells failed to mediate photosensitization, differential HCN-channel expression or biochemical activation among OFF-versus ON-ganglion cells represents a second gatekeeper for selective activation of OFF-ganglion cells in blind retinas. Overall, the photoswitches have been well tolerated in healthy and RP mouse retinas, and there have been no signs of small-molecule-mediated toxicity. Taken together, the uptake via P2X receptors and the activation of intrinsic ion channels both restrict the photosensitization of photoswitches in OFF-ganglion cells in degenerated retinas. These mechanistic insights highlight the possibility of a cell-type-specific, ''druggable'' therapeutic approach to confer light sensitivity to formerly blind retinas. This small-molecule intervention is likely to be mutation independent, although it has only been demonstrated in retinas of rd1 mice.
The results by Tochitsky et al. (2016) clearly demonstrate the need to understand the biology and pathology of retinal degeneration that can be harnessed for cell-type-specific visionrestoration approaches. However, the next steps are to test photoswitch uptake and photoswitch activation in human retinas. It will be of particular interest to determine the light intensity needed to evoke light responses. Since microbial optogenes are insensitive to room light levels and require signal amplifiers (Klapper et al., 2016) , photoswitches might improve the light sensitivity. For a successful translation, it has 
DENAQ Specifically Renders OFF-Ganglion Cells Light Sensitive in Degenerated Retinas
The wild-type retina (left) utilizes photoreceptors (rods and cones) to transduce light stimuli into electrochemical signals that are further processed by excitatory and inhibitory neuronal networks-bipolar (BC), horizontal (HC), and amacrine (AC) cells. Ganglion cells (GC) mediate the final output, encoded as trains of action potentials that are relayed to higher brain areas via the optic nerve (Opt. N.). There are two major signal pathways: ON and OFF, named after their response to onset or offset light stimuli. HCN3/4 and P2rx4/7 receptors are expressed at low levels in healthy retinas, but their expression increases in degenerated rd1 retinas (upper right). Activation of P2X receptors depends on ATP, which is elevated upon retinal degeneration. This degeneration-dependent activation of P2rx4/7 receptors in OFF-GCs leads to specific uptake of the small-molecule photoswitch DENAQ, which binds and blocks HCN channels (lower right). Upon light stimulus, its conformation changes from trans to cis, releasing the block of HCN channels. Their cAMP-dependent opening mediates a sodium influx, which depolarizes and thereby activates OFF-GCs.
to be shown that human OFF-ganglion cells are also exclusively predisposed to photoswitch uptake in degenerated retinas. There are many examples of substantial differences between rodent and human pathologies and disease phenotypes, and it is possible that the photoswitches target different cell types in human retinas. Ultimate proof will come when the first patients are treated. The advantage of applying small molecules is that development can follow the already well-established procedures for efficacy and safety testing of smallmolecule drugs, and can be assessed by the respective regulatory authorities. It is important to note that a certain photoswitch concentration threshold is crucial for function, and this requires continuous reinjection or the implantation of an infusion micropump system to deliver sufficient compound into the eye of a patient.
The photoswitches only work in functionally remodeled OFF-ganglion cell types in degenerated regions after the onset of photoreceptor degeneration. Consequently, the photoswitches could also be applied to patients that have partial retinal degeneration to enhance the remaining vision. However, photoswitches shift OFF signals to ON signals. Having both optochemical and residual intrinsic vision at work simultaneously will likely confuse the interpretation of the visual input. Therefore, this approach seems to be better suited for late-stage RP patients who also wear technical image detection devices for image inversion. Re-sensitized retinas will also lack adaption to different light levels, so medical image devices will also be needed to compensate for different light intensities to keep visual perception in the operational range of photoswitches.
Now we know how these particular photoswitches work and it may be possible to apply synthetic chemical engineering to tailor other molecules to resensitize other retinal cell types to further improve treatment. The discovery of the biological gatekeepers in degenerated retinas that restrict photoswitch activity paves the way for treating blindness in a cell-type-specific fashion using small molecules: this represents an alternative, promising, and elegant therapy for restoring vision.
In this issue of Neuron, Creed et al. (2016) describe how cocaine produces divergent forms of plasticity at synapses between specific neurons in nucleus accumbens and ventral pallidum, and how these changes are associated with positive and negative reward behaviors.
Addiction involves the transition from recreational drug use to compulsive and maladaptive drug seeking that is maintained despite negative social, financial, and health consequences (Koob and Le Moal, 2008) . Cessation of drug use is associated with the emergence of a withdrawal syndrome characterized by negative affect that promotes further drug use via negative reinforcement processes (Koob and Le Moal, 2008) . A complex interplay between ''positive'' and ''negative'' symptoms contributes to the chronic relapsing nature of addiction. Despite significant effort, effective pharmacotherapies for psychostimulant addiction are still lacking. Such slow progress is likely due in part to the propensity of preclinical investigations to study individual positive or negative addiction-related behaviors. Development of novel treatments for addiction would be significantly enhanced by identification of brain systems that modulate
